drugset / Trial / NCT07535307

Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes

NCT07535307

Phase 1 Recruiting 80 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical study is to find out how NNC0487-0111 affects, how the body uses insulin (a hormone that helps the body control blood sugar) and how well the pancreas works in people living with type 2 diabetes. There are 2 study treatments. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Timeline

Start
2026-04-10
Primary completion
2027-11-11
Completion
2027-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0487-0111 Unknown Subcutaneous